More Racura Oncology Ltd news
Racura Oncology LtdASX: RAC

RC220 Toxicology and Safety Pharmacology Studies Initiated

Oct 4, 2023 at 10:31 PM EDT · Issued by Racura Oncology Ltd

Filed with ASX · Oct 4, 2023 at 10:31 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/rc220-toxicology-and-safety-pharmacology-studies-initiated

Racura Oncology Ltd on 6ix

Earlier from Racura Oncology

  • Bisantrene cGMP API Manufacturing Completed at Laurus LabsSep 26, 2023
  • Bisantrene Shows Broad Anti-Cancer Activity in Cancer CellsSep 20, 2023
  • Race Board and Management Team ChangesAug 21, 2023
  • Race Strategic Update August 2023Aug 8, 2023
  • Race Receives Additional $1.66m R&D Tax Refund for FY 2022Jul 13, 2023

Later from Racura Oncology

  • RC220 Peripheral Infusion Safety ConfirmedOct 16, 2023
  • Trading HaltNov 2, 2023
  • Impressive Bisantrene Phase 2 AML Clinical ResultsNov 6, 2023
  • RC220 Meets Quality SpecificationsNov 8, 2023
  • Dr Daniel Tillett appointed CEO of Race OncologyNov 21, 2023
All Racura Oncology news releases↗

Follow Racura Oncology into a list and get an email when it puts out news.

Follow Racura Oncology
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer